Reteplase
| Names | |
|---|---|
| Trade names | Retavase, Retefuse, Rapilysin, Mirel, others |
| Clinical data | |
| Drug class | Tissue plasminogen activator[1] |
| Main uses | Heart attacks[1] |
| Side effects | Bleeding, allergic reaction[1] |
| External links | |
| AHFS/Drugs.com | Monograph |
| Legal | |
| License data | |
| Chemical and physical data | |
| Formula | C1736H2671N499O522S22 |
| Molar mass | 39589.75 g·mol−1 |
Reteplase, trade names include Retavase, is a thrombolytic medication primarily used to treat heart attacks.[1] It may also be used to treat certain pulmonary embolisms.[1] It is given by injection into a vein.[1]
Common side effects include bleeding.[2] Other side effects may include allergic reactions and cholesterol embolism.[1] Safety in pregnancy is unclear.[3] It is a recombinant protein form of the human tissue plasminogen activator.[1]
Reteplase was approved for medical use in the United States and Europe in 1996.[2][4] In the United States it costs about 3,600 USD per dose as of 2021.[5]
Medical uses
It should be used with 12 hours of the start of a heart attack.[4]
Mechanism of action
Reteplase is similar to recombinant human tissue plasminogen activator (alteplase), but the modifications give reteplase a longer half-life of 13–16 minutes. Reteplase also binds fibrin with lower affinity than alteplase, improving its ability to penetrate into clots.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 "Reteplase Monograph for Professionals". Drugs.com. Archived from the original on 15 August 2019. Retrieved 16 October 2021. Archived 15 August 2019 at the Wayback Machine
- ↑ 2.0 2.1 "DailyMed - RETAVASE- reteplase kit". dailymed.nlm.nih.gov. Archived from the original on 17 October 2021. Retrieved 16 October 2021. Archived 17 October 2021 at the Wayback Machine
- ↑ "Reteplase Use During Pregnancy". Drugs.com. Archived from the original on 29 November 2020. Retrieved 16 October 2021. Archived 29 November 2020 at the Wayback Machine
- ↑ 4.0 4.1 "Rapilysin". Archived from the original on 27 April 2021. Retrieved 16 October 2021. Archived 27 April 2021 at the Wayback Machine
- ↑ "Retavase Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 16 October 2021.
External links
| External sites: | |
|---|---|
| Identifiers: |
|
 | This drug article relating to the blood and blood forming organs is a stub. You can help MDWiki by expanding it. |
- Pages using duplicate arguments in template calls
- Webarchive template wayback links
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Drug has EMA link
- Chemicals that do not have a ChemSpider ID assigned
- Antithrombotic enzymes
- RTT
- All stub articles
- Blood and blood forming organ drug stubs